Metis TechBio Co., Ltd.
劑泰科技(北京)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 7666)

CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE

The board (the "**Board**") of directors (the "**Directors**") of Metis TechBio Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Ms. Cheng Yuk Ting ("**Ms. Cheng**") has resigned as a joint company secretary of the Company (the "**Joint Company Secretary**"), and an authorized representative of the Company (the "**Authorized Representative**") as required under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") with effect from June 12, 2026, and Ms. CHAN Hei ("**Ms. Chan**") has been appointed as the Joint Company Secretary and the Authorized Representative with effect from June 12, 2026. After the above changes, Dr. Chong Fu, alias Dr. Alan Fu ("**Dr. Fu**"), will remain as the other Joint Company Secretary. The biographical details of Dr. Fu and Ms. Chan are set out below:

Dr. Chong Fu (付翀), alias Dr. Alan Fu, is the chief financial officer and Board secretary of the Company. Dr. Fu is primarily responsible for the overall management of finance, investments, capital market activities, legal matters and public relations of the Group.

Prior to joining the Group, Dr. Fu served as a director from March 2023 to July 2025 and chief financial officer from October 2021 to March 2025 at IASO Biotherapeutics where he was responsible for overseeing finance, capital market activities, legal matters and business development of the company. From April 2018 to August 2021, Dr. Fu served as managing director of Haitong International Securities Group Limited, where he was primarily engaged in investment banking activities. From November 2009, Dr. Fu served as a vice president and then a director in Citigroup Inc. where he was primarily responsible for executing investment banking transactions. Prior to that, Dr. Fu worked as an associate in the law firms Davis Polk & Wardwell and Skadden, Arps, Slate, Meagher & Flom, where he was a capital markets and corporate lawyer. Dr. Fu also worked as a research scientist in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL).

Dr. Fu received his bachelor's degree of science in genetics and genetic engineering from Fudan University in July 1989. He then received his master's degree of science in cell biology from the Shanghai Institute of Biochemistry and Cell Biology, China Academy of Sciences (中國科學院生物化學與細胞生物學研究所) (formerly known as Shanghai Institute of Cell Biology (中國科學院上海細胞生物學研究所)) in June 1992. Dr. Fu received his PhD degree in molecular immunology from Washington University School of Medicine in May 1998. Dr. Fu received his Juris Doctor degree from the University of California, Berkeley in May 2004.

Dr. Fu was admitted to the State Bar of California, USA in December 2004.

Ms. CHAN Hei (陳曦) is currently a senior manager of the Company Secretarial Services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services, and has over 10 years of experience in the corporate secretarial field. Ms. Chan has been providing professional corporate services to Hong Kong listed companies, as well as multinational, private and offshore companies. Ms. Chan is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Ms. Chan holds a bachelor's degree in business administration in Accountancy from Hong Kong Polytechnic University.

Ms. Cheng has confirmed that she has no disagreement with the Board and there is no matter in relation to her resignation that needs to be brought to the attention of the shareholders of the Company and/or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Cheng for her contributions to the Company during her tenure of office and to extend our warm welcome to Ms. Chan for her new appointment.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Listing Rules, a listed issuer must appoint a company secretary who satisfies the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, by virtue of his/her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of company secretary of the listed issuer.

Reference is made to the waiver (the "**Waiver**") granted by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules by the Company in respect of the qualifications of Dr. Fu as the Joint Company Secretary during the period from May 13, 2026 (being the date on which the Company's shares are listed on the Stock Exchange) to May 12, 2029 (the "**Waiver Period**"), on the condition that Ms. Cheng will work closely with Dr. Fu to jointly discharge the duties and responsibilities as company secretary and assist Dr. Fu in acquiring the relevant experience as required under Rules 3.28 and 8.17 of the Listing Rules.

Dr. Fu currently does not possess the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. The Company has applied to the Stock Exchange for, and the Stock Exchange has also granted, a new waiver (the "**New Waiver**") from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules by the Company in respect of the remaining period of the Waiver (being the period from the date of the appointment of Ms. Chan as the Joint Company Secretary to May 12, 2029, the "**Remaining Waiver Period**"), on the conditions that: (i) Dr. Fu must be assisted by Ms. Chan during the Remaining Waiver Period; and (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes. Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Dr. Fu, having had the benefit of Ms. Chan's assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

By Order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai
Chairman of the Board, executive Director and chief executive officer

Hong Kong, June 12, 2026

As of the date of this announcement, the Board comprises Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.